-
The National Health Commission publicly solicits opinions on the Internet diagnosis and treatment regulations (draft for comments)
Time of Update: 2021-11-15
Article 10: Local health authorities at all levels shall publish to the public the list of medical institutions approved to conduct Internet diagnosis and treatment in their jurisdiction, supervision telephone numbers and other supervision methods on the provincial supervision platform, set up complaint acceptance channels, and deal with violations of laws and regulations in a timely manner .
-
Recently, many large pharmaceutical companies’ new drug R&D projects have been terminated
Time of Update: 2021-11-15
In addition to Eli Lilly, there are reports that Novartis has also decided to abandon the gene therapy AVXS-201 research and development plan in the near future .
-
The three pharmaceutical equipment industry standards will be implemented on February 1 next year!
Time of Update: 2021-11-15
According to the list of 250 industry standard numbers, names, and main contents in Annex 1, the machinery industry includes three pharmaceutical equipment industry standards, including automatic Chinese medicine decoction systems, filter integrity testers, and vaporized hydrogen peroxide concentration detectors, all of which follow It will be implemented on February 1, 2022 .
-
Following Ganli Pharmaceutical, United Laboratories, and Tonghua Dongbao, another insulin glargine was approved for listing
Time of Update: 2021-11-15
On October 26, 2021, Yichang Dongyangguang announced that insulin glargine was officially approved for listing, becoming the fourth domestic company to obtain the registration approval for this product after Ganli Pharmaceutical, United Laboratories, and Tonghua Dongbao .
-
A large number of domestic pharmaceutical companies are accelerating innovation through the License-in model
Time of Update: 2021-11-15
A large number of pharmaceutical companies are adopting the License-in model to enrich their product pipelines and accelerate innovation .
In this context, the industry believes that the capital market will still be more inclined to pharmaceutical companies with independent innovation capabilities.
-
In October, senior management changes in the pharmaceutical industry were still frequent
Time of Update: 2021-11-15
For example, the Human Resources Department of BeiGene announced to employees that the national head of blood tumor sales, Shi Hao, will leave the company on November 15, 2021, to seek external development opportunities .
-
It is getting easier to open a pharmacy, which is leading to intensified market competition
Time of Update: 2021-11-15
It is understood that in order to deepen the reform of decentralization , regulation and service, and to further reduce the time limit for the establishment of pharmaceutical companies, Zhejiang Province had cancelled the approval for the establishment of retail pharmacies as early as last year .
-
The third-generation EGFR-TKI vomitinib was successfully studied in the first-line treatment of advanced NSCLC
Time of Update: 2021-11-15
(hereinafter referred to as "Ailisi", stock code: 688578) announced its independent research and development of the third representative skin growth factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Ivesa® (Vormetinib mesylate, hereinafter referred to as "Vormetinib") is the first-line treatment for locally advanced or metastatic non-small cell lung cancer with sensitive EGFR mutations The national multicenter, randomized controlled, double-blind phase III clinical study (FURLONG) reached the primary endpoint of progression-free survival (PFS).
-
Comprehensive inventory: policies related to the life cycle management of anti-tumor drugs
Time of Update: 2021-11-15
This article counts the policies and regulations related to the research and development of anti-tumor drugs in recent years for everyone to take a look at .
-
The east wind of the biopharmaceutical industry has arrived, and the performance of upstream pharmaceutical equipment is expected to continue to increase
Time of Update: 2021-11-15
The industry believes that the east wind of the biopharmaceutical industry has arrived, and the performance of upstream pharmaceutical equipment is expected to continue to increase under the trend of domestic substitution and overseas exports .
-
The pattern of the pharmaceutical industry is about to change, and we are optimistic about these configurations in innovative drugs and the industry chain.
Time of Update: 2021-11-15
According to the data of the three quarterly reports released by Tiger Medicine, its revenue, profit attributable to the parent, and net profit deducting non-attributable to the parent in the first three quarters have increased by approximately 48%, 35%, and 75% year-on-year respectively.
-
The third quarterly report of listed pharmaceutical equipment companies is released: new opportunities in the industry appear
Time of Update: 2021-11-15
Recently, three quarterly reports of listed companies in the pharmaceutical equipment industry, including Chutian Technology, Tofflon, Xinlai Yingcai, and Canaan Technology, have been released intensively .
-
The reshuffle of the pharmaceutical manufacturing industry is imminent, and the transformation of intelligent manufacturing is the key
Time of Update: 2021-11-15
For another example, in Jiuzhitang's smart factory for solid preparations of traditional Chinese medicine, the application of the new model has significantly changed the company's previous experience of relying on people in pharmaceuticals, greatly improving work efficiency, and product quality more stable .
-
Cinda Biologicals and Xinhe Biologicals reached a strategic cooperation to jointly carry out clinical research on the combination of Sintilimab and neoantigen vaccine NEO_PLIN2101 in the treatment of tumors
Time of Update: 2021-11-15
("Xinhe Bio"), a company dedicated to creating an internationally leading AI-enabled RNA innovation Pharmaceutical’s biotechnology company jointly announced that the two parties have reached a strategic cooperation to conduct clinical research on the combination of Sintilimab injection and Neo-Bio’s personalized neoantigen vaccine NEO_PLIN2101 in the treatment of tumors .
-
A new drug research and development boom in China, and a variety of blockbuster drugs will be launched soon
Time of Update: 2021-11-15
In addition, on October 22, Sihuan Pharmaceutical also issued an announcement stating that the China National Medical Products Administration has accepted the New Drug Application (NDA) for Anaprazole Sodium Enteric-Coated Tablets .
-
my country's first "Report on the Development of Rheumatoid Arthritis in China" was officially published
Time of Update: 2021-11-15
" Director of the National Clinical Research Center for Skin and Immune Diseases, Executive Director of the Chinese Medical Doctor Association and President of Rheumatology and Immunology Branch, Beijing Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology of Xiehe Hospital, pointed out that “The Annual Report of RA” is based on patient diagnosis and treatment data from tertiary hospitals to primary medical institutions.
-
The fixed asset investment of pharmaceutical companies continues to grow, and the upstream industry is expected to enter a period of long-term steady growth
Time of Update: 2021-11-15
The industry believes that with the continued increase in fixed asset investment by pharmaceutical companies, the pharmaceutical equipment industry is expected to transform from short-term explosive growth to long-term steady growth .
-
Under the trend of innovation, the pharmaceutical industry has set off a wave of cooperation
Time of Update: 2021-11-15
On October 22, Genetron Health, which focuses on providing tumor molecular detection, cancer early screening and companion diagnostic development services, announced that it has entered into an agreement with Jiangsu Fosun Pharmaceutical Sales Co.
-
The development of PROTAC drugs is being developed at the time, and Baekje and Haisco continue to make efforts
Time of Update: 2021-11-15
Unlike traditional small molecule drugs, PROTAC does not require long-term and high-strength binding to the target protein to capture the protein and degrade it.
-
116 pharmaceutical companies released three quarterly reports, and the performance of these companies has declined
Time of Update: 2021-11-15
Among them, Tai Chi Group is one of the pharmaceutical companies with a relatively large increase in revenue and net profit in the three quarterly reports that have been published .
70% year-on-year; net profit attributable to shareholders of listed companies was 248 million yuan, an increase of 1425.
